Cidara Theraptcs Financials
Cidara Theraptcs (CDTX) reported $1.3M in revenue for fiscal year 2024, down 94.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2024 shows a financing-led balance-sheet reset, with cash rebuilt to $189.8M even as operating burn sharply widened.
From FY2023 to FY2024, operating cash flow moved from-$22.4M to-$176.5M . Yet liquidity moved the opposite way, with current ratio rising from 0.9x to 4.3x, which means the healthier balance sheet was created by new financing rather than by a self-funding business model.
Free cash flow stayed very close to operating cash flow, while capital spending was only
Revenue was just
Financial Health Signals
Scored against emerging companies for FY2024. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Cidara Theraptcs's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Cidara Theraptcs scores 13.39, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.6B) relative to total liabilities ($51.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Cidara Theraptcs passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Cidara Theraptcs reported a net loss of $169.8M while operations used $176.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Cidara Theraptcs generated $1.3M in revenue in fiscal year 2024. This represents a decrease of 94.5% from the prior year.
Cidara Theraptcs's EBITDA was -$175.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 552.9% from the prior year.
Cidara Theraptcs reported -$169.8M in net income in fiscal year 2024. This represents a decrease of 640.6% from the prior year.
Cidara Theraptcs earned -$26.75 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 409.5% from the prior year.
Cash & Balance Sheet
Cidara Theraptcs recorded an outflow of $176.7M in free cash flow in fiscal year 2024, representing a cash shortfall after capex. This represents a decrease of 670.2% from the prior year.
Cidara Theraptcs held $189.8M in cash as of fiscal year 2024; long-term debt is not reported for that period.
Not reported for fiscal year 2024.
Margins & Returns
Cidara Theraptcs's ROE was -104.0% in fiscal year 2024, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2024.
Not shown for fiscal year 2024: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2024: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Cidara Theraptcs invested $71.9M in research and development in fiscal year 2024. This represents an increase of 95.5% from the prior year.
Cidara Theraptcs invested $129K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 74.5% from the prior year.
Not reported for fiscal year 2024.
CDTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $1.3M-94.5% | $23.3M-63.9% | $64.4M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $71.9M+95.5% | $36.8M-52.5% | $77.4M+5.9% | $73.1M+7.5% | $68.0M+46.6% | $46.4M-5.6% | $49.1M+14.8% | $42.8M+20.0% | $35.7M+52.1% | $23.5M+249.9% | $6.7M+728.4% | $810K |
| SG&A Expenses | N/A | $20.6M+12.4% | $18.3M-10.8% | $20.5M+9.6% | $18.7M+17.9% | $15.9M-2.1% | $16.2M+14.8% | $14.1M+9.7% | $12.9M+1.3% | $12.7M+44.1% | $8.8M+167.3% | $3.3M+1115.4% | $272K |
| Operating Income | N/A | -$176.1M-550.8% | -$27.1M+19.2% | -$33.5M+20.7% | -$42.3M+41.2% | -$71.8M-72.2% | -$41.7M+34.1% | -$63.3M-13.6% | -$55.7M-15.0% | -$48.4M-49.9% | -$32.3M-178.0% | -$11.6M-974.2% | -$1.1M |
| Interest Expense | N/A | N/A | N/A | $2K-83.3% | $12K-42.9% | $21K-41.7% | $36K | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $0-100.0% | $15K-94.5% | $272K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | N/A | -$169.8M-640.6% | -$22.9M+31.7% | -$33.6M+20.9% | -$42.5M+41.1% | -$72.1M-75.5% | -$41.1M+30.4% | -$59.0M-5.9% | -$55.7M-15.7% | -$48.2M-49.6% | -$32.2M-170.7% | -$11.9M-785.0% | -$1.3M |
| EPS (Diluted) | — | -$26.75-409.5% | -$5.25 | -$0.48+40.7% | -$0.81+55.0% | -$1.80-31.4% | -$1.37 | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q4 FY2024 through Q3 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CDTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $214.8M+220.4% | $67.0M+41.2% | $47.5M-37.0% | $75.3M+24.7% | $60.4M-12.4% | $69.0M-12.8% | $79.1M+0.1% | $79.0M-26.1% | $107.0M-2.7% | $110.0M+351.6% | $24.4M | N/A |
| Current Assets | $210.7M+246.3% | $60.9M+35.0% | $45.1M-37.1% | $71.7M+25.4% | $57.2M-13.1% | $65.8M-14.7% | $77.1M-0.7% | $77.7M-26.3% | $105.4M-2.6% | $108.2M+370.2% | $23.0M | N/A |
| Cash & Equivalents | $189.8M+430.6% | $35.8M+9.3% | $32.7M-45.2% | $59.7M+66.2% | $35.9M-28.6% | $50.3M-32.6% | $74.6M+22.6% | $60.8M-28.8% | $85.4M+36.5% | $62.6M+174.4% | $22.8M+12222.2% | $185K |
| Inventory | N/A | $6.1M | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $1.7M-88.0% | $14.1M+141.3% | $5.8M+8.9% | $5.4M-52.1% | $11.2M+111650.0% | $10K | $0-100.0% | $321K | $0 | N/A | N/A | N/A |
| Total Liabilities | $51.5M-31.6% | $75.2M+21.5% | $61.9M+15.2% | $53.8M+8.1% | $49.7M+59.6% | $31.1M+55.9% | $20.0M+3.5% | $19.3M+2.7% | $18.8M+209.8% | $6.1M-83.1% | $35.8M | N/A |
| Current Liabilities | $49.6M-26.5% | $67.4M+62.8% | $41.4M+21.7% | $34.0M-11.8% | $38.6M+27.7% | $30.2M+51.8% | $19.9M+64.6% | $12.1M+35.6% | $8.9M+49.1% | $6.0M+85.9% | $3.2M | N/A |
| Total Equity | $163.3M+2089.1% | -$8.2M+43.1% | -$14.4M-210.2% | $13.1M+22.3% | $10.7M-71.7% | $37.8M-36.0% | $59.1M-1.0% | $59.7M-32.2% | $88.2M-15.1% | $103.9M+1007.9% | -$11.4M-718.7% | -$1.4M |
| Retained Earnings | -$611.3M-38.5% | -$441.4M-5.5% | -$418.5M-11.0% | -$377.2M-12.7% | -$334.7M-28.8% | -$259.8M-18.8% | -$218.7M-46.4% | -$149.4M-59.5% | -$93.7M-105.9% | -$45.5M-242.0% | -$13.3M | N/A |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
CDTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$132.9M | -$176.5M-687.0% | -$22.4M+21.2% | -$28.5M-12.8% | -$25.2M+53.6% | -$54.4M-90.7% | -$28.5M+49.7% | -$56.7M-13.6% | -$49.9M-25.5% | -$39.8M-53.2% | -$26.0M-236.7% | -$7.7M-635.7% | -$1.0M |
| Capital Expenditures | $0 | $129K-74.5% | $505K+328.0% | $118K+187.8% | $41K-78.0% | $186K+431.4% | $35K-80.2% | $177K-42.2% | $306K-23.7% | $401K-65.7% | $1.2M+18.1% | $991K | N/A |
| Free Cash Flow | -$132.9M | -$176.7M-670.2% | -$22.9M+19.8% | -$28.6M-13.1% | -$25.3M+53.7% | -$54.6M-91.1% | -$28.6M+49.8% | -$56.9M-13.3% | -$50.2M-25.0% | -$40.2M-48.1% | -$27.1M-211.8% | -$8.7M | N/A |
| Investing Cash Flow | -$176.3M | -$129K+74.5% | -$505K-328.0% | -$118K-187.8% | -$41K+78.0% | -$186K-431.4% | -$35K-100.2% | $14.3M+219.9% | $4.5M-82.5% | $25.5M | N/A | N/A | N/A |
| Financing Cash Flow | $481.8M | $337.1M+1197.2% | $26.0M+2832.3% | -$951K-102.1% | $44.6M+19.6% | $37.3M+161.2% | $14.3M-74.6% | $56.2M+168.9% | $20.9M-43.7% | $37.1M | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0-100.0% | $79K | $0 | $0 | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q4 FY2024 through Q3 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CDTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -13811.9% | -116.2% | -52.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -13319.8% | -98.5%-46.4pp | -52.1% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -104.0% | N/A | N/A | -324.1%+348.9pp | -673.0%-564.4pp | -108.6%-8.8pp | -99.8%-6.5pp | -93.3%-38.7pp | -54.6%-23.6pp | -31.0% | N/A | N/A |
| Return on Assets | -79.1%-44.8pp | -34.2%+36.5pp | -70.7%-14.3pp | -56.4%+63.0pp | -119.3%-59.8pp | -59.6%+15.0pp | -74.6%-4.1pp | -70.5%-25.5pp | -45.0%-15.8pp | -29.3%+19.6pp | -48.9% | N/A |
| Current Ratio | 4.25+3.4x | 0.90-0.2x | 1.09-1.0x | 2.11+0.6x | 1.48-0.7x | 2.18-1.7x | 3.88-2.5x | 6.43-5.4x | 11.83-6.3x | 18.11+11.0x | 7.16 | N/A |
| Debt-to-Equity | 0.32 | N/A | N/A | 4.10-0.5x | 4.64+3.8x | 0.82+0.5x | 0.340.0x | 0.32+0.1x | 0.21+0.2x | 0.06 | N/A | N/A |
| FCF Margin | -13855.8% | -98.5%-54.1pp | -44.4% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Cidara Theraptcs Ranks
Frequently Asked Questions
What is Cidara Theraptcs's annual revenue?
Cidara Theraptcs (CDTX) reported $1.3M in total revenue for fiscal year 2024. This represents a -94.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cidara Theraptcs's revenue growing?
Cidara Theraptcs (CDTX) revenue declined by 94.5% year-over-year, from $23.3M to $1.3M in fiscal year 2024.
Is Cidara Theraptcs profitable?
No, Cidara Theraptcs (CDTX) reported a net income of -$169.8M in fiscal year 2024.
What is Cidara Theraptcs's EBITDA?
Cidara Theraptcs (CDTX) had EBITDA of -$175.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cidara Theraptcs's return on equity (ROE)?
Cidara Theraptcs (CDTX) has a return on equity of -104.0% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Cidara Theraptcs's free cash flow?
Cidara Theraptcs (CDTX) recorded an outflow of $176.7M in free cash flow during fiscal year 2024. This represents a -670.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cidara Theraptcs's operating cash flow?
Cidara Theraptcs (CDTX) recorded an outflow of $176.5M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Cidara Theraptcs's total assets?
Cidara Theraptcs (CDTX) had $214.8M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Cidara Theraptcs's capital expenditures?
Cidara Theraptcs (CDTX) invested $129K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Cidara Theraptcs spend on research and development?
Cidara Theraptcs (CDTX) invested $71.9M in research and development during fiscal year 2024.
What is Cidara Theraptcs's current ratio?
Cidara Theraptcs (CDTX) had a current ratio of 4.25 as of fiscal year 2024, which is generally considered healthy.
What is Cidara Theraptcs's debt-to-equity ratio?
Cidara Theraptcs (CDTX) had a debt-to-equity ratio of 0.32 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cidara Theraptcs's return on assets (ROA)?
Cidara Theraptcs (CDTX) had a return on assets of -79.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Cidara Theraptcs's cash runway?
Based on fiscal year 2024 data, Cidara Theraptcs (CDTX) had $189.8M in cash against an annual operating cash burn of $176.5M. This gives an estimated cash runway of approximately 13 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Cidara Theraptcs's Altman Z-Score?
Cidara Theraptcs (CDTX) has an Altman Z-Score of 13.39, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cidara Theraptcs's Piotroski F-Score?
Cidara Theraptcs (CDTX) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cidara Theraptcs's earnings high quality?
Cidara Theraptcs (CDTX) reported a net loss of $169.8M while operations used $176.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Cidara Theraptcs?
Cidara Theraptcs (CDTX) scores 51 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.